Description
Letrozole is a third-generation nonsteroidal cell-permeable aromatase inhibitor (IC₅₀ = 2 nM). It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Useful in the treatment of postmenopausal breast cancer.
Letrozole is a third-generation nonsteroidal cell-permeable aromatase inhibitor (IC₅₀ = 2 nM). It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Useful in the treatment of postmenopausal breast cancer.
Alternate Name/Synonyms: 4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile
Appearance: White to off-white solid
Formulation: N/A
CAS Number: 112809-51-5
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: No
Molecular Formula: C₁₇H₁₁N₅
Molecular Weight: 285.3
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (>50 mg/ml)
Handling: Protect from air and moisture
Country of Origin: USA
Tag Line: A nonsteroidal aromatase inhibitor
MDL Number: MFCD00866241
PubChem CID: 3902
SMILES: C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
InChi: InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
InChi Key: HPJKCIUCZWXJDR-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |